Alternative splicing variations in mouse CAPS2: differential expression and functional properties of splicing variants
© Sadakata et al; licensee BioMed Central Ltd. 2007
Received: 09 February 2007
Accepted: 12 April 2007
Published: 12 April 2007
Ca2+-dependent activator protein 2 (CAPS2/CADPS2) is a secretory vesicle-associated protein involved in the release of neurotrophin. We recently reported that an aberrant, alternatively spliced CAPS2 mRNA that lacks exon 3 (CAPS2Δexon3) is detected in some patients with autism. Splicing variations in mouse CAPS2 and their expression and functions remain unclear.
In this study, we defined 31 exons in the mouse CAPS2 gene and identified six alternative splicing variants, CAPS2a-f. CAPS2a is an isoform lacking exons 22 and 25, which encode part of the Munc13-1-homologous domain (MHD). CAPS2b lacks exon 25. CAPS2c lacks exons 11 and 22. CAPS2d, 2e, and 2f have C-terminal deletions from exon 14, exon 12, and exon 5, respectively. On the other hand, a mouse counterpart of CAPS2Δexon3 was not detected in the mouse tissues tested. CAPS2b was expressed exclusively in the brain, and the other isoforms were highly expressed in the brain, but also in some non-neural tissues. In the brain, all isoforms showed predominant expression patterns in the cerebellum. In the developing cerebellum, CAPS2b showed an up-regulated expression pattern, whereas the other isoforms exhibited transiently peaked expression patterns. CAPS2 proteins were mostly recovered in soluble fractions, but some were present in membrane fractions, except for CAPS2c and 2f, both of which lack the PH domain, suggesting that the PH domain is important for membrane association. In contrast to CAPS2a and 2b, CAPS2c showed slightly decreased BDNF-releasing activity, which is likely due to the C-terminal truncation of the PH domain in CAPS2c.
This study indicates that, in mouse, there are six splicing variants of CAPS2 (CAPS2a-f), and that these are subdivided into two groups: a long form containing the C-terminal MHD and a short form lacking the C-terminal MHD. These results demonstrate that the splicing variations correlate with their expression patterns and intracellular distribution, and affect BDNF release; however, whether or not the short forms possess activities other than BDNF release, for example as natural dominant-negative isoforms, remains to be determined.
The Ca2+-dependent activator protein for secretion (CAPS/CADPS) family consists of two members, CAPS1/CADPS1 [1–3] and CAPS2/CADPS2 [4–6]. CAPS1 was shown to play a role in the ATP-dependent priming step of Ca2+-triggered dense-core vesicle (DCV) exocytosis by binding to both phosphatidyl inositol 4,5-bisphosphate and DCVs in response to Ca2+ increase [7, 8]; it also interacts with the dopamine receptor . A study of CAPS1-deficient mice suggested that CAPS1 is involved in catecholamine loading of DCVs in embryonic chromaffin cells . On the other hand, CAPS2 is associated with secretory vesicles containing the neurotrophins BDNF and NT-3 in the parallel fiber terminals of cerebellar granule cells, and is involved in the release of BDNF and NT-3 . CAPS2 is widely localized across various brain regions, and shows overlapping distribution patterns with BDNF in many areas . Our recent studies of CAPS2-deficient mice indicated that CAPS2 plays pivotal roles in BDNF release, cellular phenotypes (e.g., neuronal survival and differentiation, synapse structure and function), and behavioral phenotypes (e.g., water-maze spatial learning, anxiety, circadian rhythm, maternal behavior) [12, 13].
The expression of an aberrant splicing variant of CAPS2 in some patients with autism has also been reported . The autistic isoform, CAPS2Δexon3, is missing exon 3, which encodes the dynactin 1-interacting domain (DID) . Exogenously expressed CAPS2Δexon3 failed to localize to axons but accumulated in somato-dendritic areas in cultured cerebellar and cortical neurons, suggesting a possible disturbance of local CAPS2-mediated neurotrophin release . In this study, we further explore splicing variations in CAPS2 and identified five additional splice isoforms. We characterized the expression patterns and neurotrophin release properties of these isoforms.
Results and discussion
We examined the patterns of CAPS2 splicing during cerebellar development, by RT-PCR using specific primer sets for each isoform. CAPS2b is the only isoform that contains exon 22. Therefore, RT-PCR with a primer pair spanning exon 21-exon 23 resulted in a longer band (267 bp) for CAPS2b in addition to a shorter band (147 bp) for CAPS2a and 2c. Interestingly, there was a peak in the expression of CAPS2a and/or 2c at P7, whereas CAPS2b was up-regulated throughout development (Figure 3B). The expression of CAPS2d reached a peak at P7 and decreased thereafter, whereas that of both CAPS2e and 2f reached a peak between P12 and P21.
Among the eight mouse tissues tested, the brain, lung, kidney, and testis showed expression of all isoforms except for CAPS2b (Figure 3C). Interestingly, expression of CAPS2b was detectable only in the brain. Among these isoforms, the expression level of CAPS2f was the lowest as shown by its requiring the highest cycle number of PCR cycles to detect it (numerals within the parenthesis of Figure 3B, C).
We next examined the expression of the endogenous proteins produced from these splice isoform mRNAs in the mouse brain. Immunoreactive bands corresponding to short isoforms (CAPS2d-f) were observed at low to undetectable protein levels in the mouse cerebellum (Figure 5B). In addition, the previous report showed that in non-neural tissue such as pituitary, lung, pancreas and kidney, only a 150 kDa band immunoreactive for CAPS2 was detected . At the mRNA level, more reaction cycles and time were needed for the amplification of transcripts encoding the short isoforms by RT-PCR and for the colorimetric detection of transcripts by in situ hybridization, respectively, indicating that the expression levels of the genes encoding the short isoforms are very low. These results indicate that the function of CAPS2 in vivo is apparently due to the long isoforms (CAPS2a-c) rather than the short isoforms (CAPS2d-f). However, the functional role(s) of the short isoforms remain to be studied.
Interestingly, expression of the exon 22-containing isoform was up-regulated in the developing mouse cerebellum, whereas exon 22-skipped isoforms were expressed transiently, peaking at P7. Moreover, the exon 22-containing isoform showed higher BDNF-releasing activity than other long isoforms (Figure 3B). On the other hand, as described in our previous report, CAPS2 immunoreactivities are detected in both the soma and axon of cerebellar granule cells at P7, but almost exclusively in the axon at P21 . These results suggest that the exon 22 splicing patterns are related to high releasing activity and axonal localization in cerebellar granule cells. CAPS2-mediated regulation of neurotrophin actions in terms of their releasing dose and subcellular localization may be important for normal cerebellar development.
The splicing of exon 22 is interesting for reasons other than the developmental differences in expression; that is, the exon 22-containing isoform was detectable only in the brain, whereas exon 22-skipped isoforms were widely expressed in various tissues. Exon 22 encodes part of the MHD, specifically a proline-rich domain (8 prolines within 40 residues). Proline-rich motifs occurred often in many protein-protein interaction sites, including one recognized by the Src homology 3 (SH3) domain. Our preliminary screening of protein candidates that interact with the exon 22-encoded region, by yeast two-hybrid, isolated five candidates; however, none of these had an SH3 domain (data not shown). Future analyses of CAPS2 proline-rich domain-interacting proteins will clarify the significance of the alternative splicing of exon 22.
We explored the alternative splicing diversity of CAPS2 and identified six CAPS2 isoforms. The alternative splicing of exon 22 (presence or absence) was associated with a difference in tissue distribution and a developmental expression pattern. Our study showed that an intact PH domain is required for the association of CAPS2 with the membrane and efficient BDNF release activity. On the other hand, exon 3-skipping, found in autistic patients, was not observed in the mouse tissues tested.
All experimental protocols were approved by the RIKEN Institutional Animal Care and Use Committee.
Cloning of mouse CAPS2 splicing variants
DNA containing exons 4 and 5 of CAPS2 was used as a probe to clone mouse CAPS2 splicing variant cDNAs. Approximately 1 × 106 plaques of a cDNA library constructed from P6 cerebella of C57BL/6j mice (a kind gift from Dr. M. E. Hatten, Rockefeller University, New York, NY) were screened using a 32P-labeled probe. Sequencing was performed in both directions by the dideoxy chain termination method using [α-32P] dCTP and the BcaBest dideoxy sequencing kit (Takara Bio, Otsu, Shiga, Japan).
A series of first-strand cDNAs was produced by reverse-transcription (RT) from 20 ng of total RNA derived from ICR mice using an oligo-dT primer. The cycling conditions were as follows: denaturing at 94°C for 3 min, amplification by cycles of 95°C (30 s), 60°C (30 s), and 72°C (1 min), and extension at 72°C for 5 min. Primers were as follows. Mouse CAPS2 exon 21–23 forward primer: 5'-GACCTGATGGAGTCTGC-3'; exon 21–23 reverse primer: 5'-CCAATGGAGATCAAAGACGAAC-3' (CAPS2b product: 267 bp; CAPS2a, c product: 147 bp); CAPS2d forward primer: 5'-GCTGTCATTGACCCCAC-3'; CAPS2d reverse primer: 5'-GATGAAACAACCCCAGTCAC-3' (CAPS2d PCR product: 220 bp); CAPS2e forward primer: 5'-CAACGCTGTTAAAGAGGGAG-3'; CAPS2e reverse primer: 5'-GCTTCAATTTTGTGTTTTATTAAGGTTATTATTTGATAATC-3' (CAPS2e PCR product: 240 bp); CAPS2f forward primer: 5'-CTGAGTAAGGAGCAGCTC-3'; CAPS2f reverse primer: 5'-GGCCAAGGCAGAAAGGT-3' (CAPS2f PCR product: 225 bp). RT-PCR of mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with the primers 5'-GCCATCAACGACCCCTTCATTGACCTC-3' (forward primer) and 5'-GCCATGTAGGCCATGAGGTCCACCAC-3' (reverse primer) was used as an internal control.
DNA sequences corresponding to various exons of CAPS2 (exon 11, exon 22, CAPS2d-specific exon, CAPS2e-specific exon, and CAPS2f-specific exon) were used as templates to prepare digoxigenin-labeled antisense riboprobes using a digoxigenin-dUTP labeling kit (Roche Diagnostics, Indianapolis, IN, USA). Eight μm sections of 4% paraformaldehyde-fixed, paraffin-embedded P7 and P21 mouse brains were deparaffinized and treated with a proteinase K solution (10 ng/μl in PBS; Invitrogen, Carlsbad, CA, USA) at room temperature for 15 min. After acetylation, sections were incubated in a hybridization buffer containing 500 ng/μl digoxigenin-labeled riboprobes, at 60°C overnight, in a humidified chamber. Hybridized sections were washed by successive immersion in 2 × SSC, 50% formamide (at 60°C for 20 min, twice), TNE (1 mM EDTA, 0.5 M NaCl, 10 mM Tris-HCl, pH 8.0, at 37°C for 10 min), TNE containing 20 ng/μl RNase A (at 37°C for 30 min), 2 × SSC (at room temperature for 10 min, twice), and 0.2× SSC (at 60°C for 30 min, twice). The hybridization signals were detected using a digoxigenin detection kit (Roche diagnostics).
Subcellular fractionation was performed as described previously . Mouse CAPS2 cDNAs were subcloned into the pEF-BOS vector containing the EF-1α promoter  and a C-terminal hemagglutinin (HA) tag to create pEF-BOS-CAPS2-HA. PC12 cells (1 × 106 cells) transfected with pEF-BOS-CAPS2-HA constructs, using LIPOFECTAMINE 2000 Reagent (Invitrogen) according to the manufacturer's instructions, were harvested 1 day after transfection and suspended in 1 ml of a homogenization buffer (10 mM Tris-HCl (pH 7.5), 0.32 M sucrose, 1 mM EDTA and a 1× cocktail of protease inhibitors) and passed five times through a 26-gauge needle. The homogenate was centrifuged at 1,000 × g for 10 min at 4°C. The supernatant was further centrifuged at 100,000 × g for 1 h at 4°C and the resulting supernatant was saved as the cytosolic fraction. The pellet was resuspended in 1 ml of homogenization buffer (crude membrane fraction). Protein concentrations in each fraction were quantified using bicinchoninic acid (BCA protein assay; Pierce, Rockford, IL, USA), and equal amounts of protein were separated by SDS-PAGE and subjected to Western blotting.
Preparation of subcellular fractions
P56 C57BL/6J male mice were sacrificed after anesthesia with diethyl ether. Mouse cerebella were dissected and homogenized in ice-cold homogenization buffer (50 mM HEPES [pH 7.4], 150 mM NaCl, 10% Glycerol, 1% Triton X-100, 5 mM EDTA, protease inhibitor cocktail) using a glass/Teflon homogenizer. Homogenates were centrifuged at 20,000 × g for 10 min at 4°C. The protein concentrations of lysates were quantified using a BCA protein assay. Ten μg of protein was separated by SDS-PAGE and subjected to Western blotting.
Guinea pig polyclonal anti-CAPS2 antibody raised against the GST-tagged CAPS2 (aa 18–89)  and rat monoclonal anti-HA antibody (cat. no. 1867423, Boehringer Mannheim, Indianapolis, IN, USA) were used for Western blotting (used at dilution of 1:10,000 and 1:1,000, respectively).
Mouse BDNF cDNA was subcloned into the pEF4/Myc-His plasmid vector containing the EF-1α promoter (Invitrogen) to create pEF4/Myc-His-BDNF. Mouse CAPS2 cDNA was subcloned into the pcDNA3 plasmid vector containing the CMV promoter (Invitrogen) to create pcDNA3-CAPS2. Transfections were carried out in 24-well plates, using LIPOFECTAMINE 2000 Reagent (Invitrogen) as described previously . For these experiments we applied LIPOFECTAMINE complexed with 1 μg of pcDNA3-CAPS2 and 0.05 μg of pEF4/Myc-His-BDNF plasmid DNAs to PC12 cells. Following 5 h of incubation with the LIPOFECTAMINE and plasmid DNA complexes, cells were washed and grown in normal medium. At 24 h after transfection, PC12 cells were incubated in fresh assay medium (DMEM containing 0.2% BSA) for 10 min. Two different DMEMs were used: standard DMEM (11965; Invitrogen) and high-KCl DMEM (50 mM KCl, 65 mM NaCl based on 11965; specially ordered; Invitrogen). Both DMEMs were fully equilibrated in a 5% CO2 atmosphere at 37°C before application. Culture media were collected after control and high-KCl stimulation assays, and the neurotrophin concentration (pg/ml) was measured using the BDNF Emax ImmunoAssay System (Promega, Madison, WI, USA) according to the manufacturer's instructions.
Statistical analysis was performed using Statcel software (OMS, Saitama, Japan). Data were compared using the Student's t test or the Mann-Whitney U test according to unequal or equal variance. Comparisons between groups of splicing variants were made using one-way ANOVA. A P value of <0.05 was considered statistically significant.
We are grateful to Dr. Jin-hong Huang and CDT-DB team members of our lab for help with mouse brain analysis. We also thank Dr. M.E. Hatten (Rockefeller University) for the cerebellar cDNA library. This study was supported by grants-in-aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (Grant number: 17700322 to TS), the Japan Society for the Promotion of Science (JSPS), and the Institute of Physical and Chemical Research (RIKEN).
- Renden R, Berwin B, Davis W, Ann K, Chin CT, Kreber R, Ganetzky B, Martin TF, Broadie K: Drosophila CAPS is an essential gene that regulates dense-core vesicle release and synaptic vesicle fusion. Neuron. 2001, 31: 421-437. 10.1016/S0896-6273(01)00382-8.PubMedView ArticleGoogle Scholar
- Berwin B, Floor E, Martin TF: CAPS (mammalian UNC-31) protein localizes to membranes involved in dense-core vesicle exocytosis. Neuron. 1998, 21: 137-145. 10.1016/S0896-6273(00)80521-8.PubMedView ArticleGoogle Scholar
- Tandon A, Bannykh S, Kowalchyk JA, Banerjee A, Martin TF, Balch WE: Differential regulation of exocytosis by calcium and CAPS in semi-intact synaptosomes. Neuron. 1998, 21: 147-154. 10.1016/S0896-6273(00)80522-X.PubMedView ArticleGoogle Scholar
- Cisternas FA, Vincent JB, Scherer SW, Ray PN: Cloning and characterization of human CADPS and CADPS2, new members of the Ca2+-dependent activator for secretion protein family. Genomics. 2003, 81: 279-291. 10.1016/S0888-7543(02)00040-X.PubMedView ArticleGoogle Scholar
- Speidel D, Varoqueaux F, Enk C, Nojiri M, Grishanin RN, Martin TF, Hofmann K, Brose N, Reim K: A family of Ca2+-dependent activator proteins for secretion: comparative analysis of structure, expression, localization, and function. J Biol Chem. 2003, 278: 52802-52809. 10.1074/jbc.M304727200.PubMedView ArticleGoogle Scholar
- Sadakata T, Mizoguchi A, Sato Y, Katoh-Semba R, Fukuda M, Mikoshiba K, Furuichi T: The secretory granule-associated protein CAPS2 regulates neurotrophin release and cell survival. J Neurosci. 2004, 24: 43-52. 10.1523/JNEUROSCI.2528-03.2004.PubMedView ArticleGoogle Scholar
- Grishanin RN, Klenchin VA, Loyet KM, Kowalchyk JA, Ann K, Martin TF: Membrane association domains in Ca2+-dependent activator protein for secretion mediate plasma membrane and dense-core vesicle binding required for Ca2+-dependent exocytosis. J Biol Chem. 2002, 277: 22025-22034. 10.1074/jbc.M201614200.PubMedView ArticleGoogle Scholar
- Grishanin RN, Kowalchyk JA, Klenchin VA, Ann K, Earles CA, Chapman ER, Gerona RR, Martin TF: CAPS acts at a prefusion step in dense-core vesicle exocytosis as a PIP2 binding protein. Neuron. 2004, 43: 551-562. 10.1016/j.neuron.2004.07.028.PubMedView ArticleGoogle Scholar
- Binda AV, Kabbani N, Levenson R: Regulation of dense core vesicle release from PC12 cells by interaction between the D2 dopamine receptor and calcium-dependent activator protein for secretion (CAPS). Biochem Pharmacol. 2005, 69: 1451-1461. 10.1016/j.bcp.2005.02.015.PubMedView ArticleGoogle Scholar
- Speidel D, Bruederle CE, Enk C, Voets T, Varoqueaux F, Reim K, Becherer U, Fornai F, Ruggieri S, Holighaus Y, Weihe E, Bruns D, Brose N, Rettig J: CAPS1 regulates catecholamine loading of large dense-core vesicles. Neuron. 2005, 46: 75-88. 10.1016/j.neuron.2005.02.019.PubMedView ArticleGoogle Scholar
- Sadakata T, Itakura M, Kozaki S, Sekine Y, Takahashi M, Furuichi T: Differential distributions of the Ca2+-dependent activator protein for secretion family proteins (CAPS2 and CAPS1) in the mouse brain. J Comp Neurol. 2006, 495: 735-753. 10.1002/cne.20947.PubMedView ArticleGoogle Scholar
- Sadakata T, Washida M, Iwayama Y, Shoji S, Sato Y, Ohkura T, Katoh-Semba R, Nakajima M, Sekine Y, Tanaka M, Nakamura K, Iwata Y, Tsuchiya KJ, Mori N, Detera-Wadleigh SD, Ichikawa H, Itohara S, Yoshikawa T, Furuichi T: Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients. J Clin Invest. 2007, 117: 931-943. 10.1172/JCI29031.PubMedPubMed CentralView ArticleGoogle Scholar
- Sadakata T, Kakegawa W, Mizoguchi A, Washida M, Katoh-Semba R, Shutoh F, Okamoto T, Nakashima H, Kimura K, Tanaka M, Sekine Y, Itohara S, Yuzaki M, Nagao S, Furuichi T: Impaired cerebellar development and function in mice lacking CAPS2, a protein involved in neurotrophin release. J Neurosci. 2007, 27: 2472-2482. 10.1523/JNEUROSCI.2279-06.2007.PubMedView ArticleGoogle Scholar
- Sadakata T, Furuichi T: Identification and mRNA expression of Ogdh, QP-C, and two predicted genes in the postnatal mouse brain. Neurosci Lett. 2006, 405: 217-222. 10.1016/j.neulet.2006.07.008.PubMedView ArticleGoogle Scholar
- Sadakata T, Washida M, Morita N, Furuichi T: Tissue distribution of Ca2+-dependent activator protein for secretion family members CAPS1 and CAPS2 in mice. J Histochem Cytochem. 2007, 55: 301-311. 10.1369/jhc.6A7033.2006.PubMedView ArticleGoogle Scholar
- van Rossum DB, Patterson RL, Sharma S, Barrow RK, Kornberg M, Gill DL, Snyder SH: Phospholipase Cgamma1 controls surface expression of TRPC3 through an intermolecular PH domain. Nature. 2005, 434: 99-104. 10.1038/nature03340.PubMedView ArticleGoogle Scholar
- Fukuda M, Mikoshiba K: Characterization of KIAA1427 protein as an atypical synaptotagmin (Syt XIII). Biochem J. 2001, 354: 249-257. 10.1042/0264-6021:3540249.PubMedPubMed CentralView ArticleGoogle Scholar
- Mizushima S, Nagata S: pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 1990, 18: 5322-10.1093/nar/18.17.5322.PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.